Back to Search
Start Over
Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine
- Source :
- Vaccine. 35(37)
- Publication Year :
- 2017
-
Abstract
- Background The 9-valent HPV (9vHPV) vaccine was developed to prevent infection and disease related to 9 HPV types (HPV6/11/16/18/31/33/45/52/58) which cause approximately 90% of cervical cancers, HPV-related vulvar, vaginal and anal cancers, and genital warts worldwide. In a pivotal efficacy study, the 9vHPV vaccine prevented infection and disease due to the 9 vaccine types. Duration of protection remains to be determined. Vaccines that induce long-term protection are generally characterized by the generation of immune memory. The purpose of this report is to assess the persistence of HPV antibody response and existence of immune memory at 5 years post-vaccination. Methods A subset of subjects (N = 150) who received 3 doses of 9vHPV vaccine at day 1, month 2 and month 6 in the pivotal efficacy study continued in a study extension and received a fourth dose of 9vHPV vaccine at month 60. Serum HPV antibody levels were measured pre-dose 4 and at 7 and 28 days post-dose 4 by competitive Luminex immunoassay. Adverse events were assessed using a vaccination report card. Results HPV antibodies induced following the 3-dose series of 9vHPV vaccine in the base study persisted through month 60 with seropositivity rates ranging from 77.5% to 100%. Geometric mean titers at 1 week and 1 month post-dose 4 were 1.25–4.10 and 1.65–4.88-fold higher, respectively, than levels observed 1 month following the completion of the three-dose primary series. Seropositivity rates were >99% and 100% at 1 week and 1 month post-dose 4, respectively. The fourth dose of 9vHPV vaccine was generally well tolerated. Conclusions A three-dose regimen of the 9vHPV vaccine induced persistent HPV antibody response through 5 years post-vaccination. Administration of a fourth dose resulted in a strong anamnestic response to all 9 vaccine types. These findings suggest that the efficacy of the 9vHPV vaccine will be long lasting. Clinical Trials.gov Identifier: NCT00543543 .
- Subjects :
- 0301 basic medicine
Adult
Male
Antibodies, Viral
Genital warts
03 medical and health sciences
Young Adult
0302 clinical medicine
Medicine
Humans
030212 general & internal medicine
Papillomavirus Vaccines
Adverse effect
Immunization Schedule
General Veterinary
General Immunology and Microbiology
biology
business.industry
Immunogenicity
Papillomavirus Infections
Public Health, Environmental and Occupational Health
medicine.disease
Vaccination
Clinical trial
Titer
Regimen
030104 developmental biology
Infectious Diseases
Immunology
biology.protein
Molecular Medicine
Female
Antibody
business
Subjects
Details
- ISSN :
- 18732518 and 00543543
- Volume :
- 35
- Issue :
- 37
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....3709db593ec933f8d1f8a88ac603d1c1